Achilles Therapeutics Plc (ACHL) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Achilles Therapeutics Plc announced strong financial results for Q1 2024, with a cash reserve of $112.3 million, extending their operational runway through 2025. The company reported interim Phase I/IIa data on T cell therapies for advanced cancers, noting improvements and anticipating further data in the latter half of 2024. Research and development expenses decreased, contributing to a smaller net loss compared to the previous year.
For further insights into ACHL stock, check out TipRanks’ Stock Analysis page.
